TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31063264

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Workshop intervention
Number of subjects: 0
Study: 28644207

Group type: EXPERIMENTAL
Intervention: Enzymatic debridement with bromelain (NexoBrid, EDNX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional surgical debridement (TSD)
Number of subjects: 40
Study: 26715040

Group type: EXPERIMENTAL
Intervention: Augmented cognitive behavioural therapy (augmented CBT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Computerized cognitive training program (CogniPlus)
Number of subjects: 61
Study: 24220557

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU)
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus oxaliplatin (FU + oxaliplatin)
Number of subjects: 892

Group type: COMPARATOR
Intervention: Control group (FU)
Number of subjects: 892
Study: 21720653

Group type: EXPERIMENTAL
Intervention: Citrus bioflavonoid blend
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19192463

Group type: EXPERIMENTAL
Intervention: Continuation and maintenance antidepressant medication
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Baseline predictors (higher level of personality pathology and higher level of education)
Number of subjects: 91
Study: 16292319

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 15215815

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d for 1 week) plus Clopidogrel (75 mg/d for 3 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Warfarin (international normalized ratio, 2 to 3 for 3 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aspirin plus Clopidogrel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 30
Study: 10679542

Group type: EXPERIMENTAL
Intervention: Therapeutic NCPAP
Number of subjects: 59

Group type: COMPARATOR
Intervention: Subtherapeutic NCPAP
Number of subjects: 59
Study: 9316956

Group type: EXPERIMENTAL
Intervention: Halothane at 0.5 MAC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.5 MAC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Halothane, Isoflurane, Sevoflurane at 1.5 MAC for 3 hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isoflurane and Sevoflurane during burst suppression
Number of subjects: 24
Study: 8398293

Group type: EXPERIMENTAL
Intervention: Clodronate (1.6 g daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Calcitonin (100 U)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3598328

Group type: EXPERIMENTAL
Intervention: Intravenous alpha-2 interferon (50 X 10(6) U/m2) on 5 consecutive days every 4 weeks
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subcutaneous alpha-2 interferon (20 X 10(6) U/m2) three times per week
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intravenous alpha-2 interferon (20 X 10(6) U/m2 per day) in combination with intravenous 5-Fluorouracil (250-500 mg/m2 per day on the first 5 days of each 4-week cycle)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subcutaneous alpha-2 interferon (5 X 10(6) U/m2 per day) in combination with intravenous 5-Fluorouracil (250-500 mg/m2 per day on the first 5 days of each 4-week cycle)
Number of subjects: 65
Study: 30924792

Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) for managing chronic ulcers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) for surgical site infection (SSI) surveillance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) for postoperative wound care
Number of subjects: 0
Study: 28606437

Group type: EXPERIMENTAL
Intervention: Price-aware group (surgeons received implant prices)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Price-naïve group (surgeons did not receive implant prices)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Price-aware group
Number of subjects: 226

Group type: COMPARATOR
Intervention: Price-naïve group
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 226
Study: 26271904

Group type: EXPERIMENTAL
Intervention: Choline supplementation (2 grams of choline bitartrate)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23419552

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) programme
Number of subjects: 199

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: iCBT in primary care setting
Number of subjects: 199
Study: 21366899

Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Procalcitonin and CRP
Number of subjects: 87
Study: 18362366

Group type: EXPERIMENTAL
Intervention: Thalidomide plus dexamethasone (thal/dex)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo plus dexamethasone (placebo/dex)
Number of subjects: 470
Study: 19460056

Group type: EXPERIMENTAL
Intervention: Heated humidification with CPAP (Fisher & Paykel HC201 pump with built-in heated humidification)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-humidification with CPAP (heater disabled and without water)
Number of subjects: 54
Study: 16359965

Group type: EXPERIMENTAL
Intervention: Müllerian-inhibiting substance (MIS)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Inhibin B
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone (LH)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Androstenedione (A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fasting insulin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ovarian volume
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pulsatility index
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlation of Inhibin B with MIS
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlation of MIS with ovarian size
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlation of MIS with reproductive hormones and insulin
Number of subjects: 46
Study: 12099157

Group type: EXPERIMENTAL
Intervention: Voltaren Ophtha CD
Number of subjects: 299

Group type: COMPARATOR
Intervention: Voltaren Ophtha
Number of subjects: 299
Study: 9496522

Group type: EXPERIMENTAL
Intervention: Octreotide 0.1 mg subcutaneously 30 min before and 8 and 16 hours after ERCP
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 8974349

Group type: EXPERIMENTAL
Intervention: Alcoholics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzodiazepine-treated normal volunteers
Number of subjects: 0
Study: 3052555

Group type: EXPERIMENTAL
Intervention: Active transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inactive transcutaneous electrical nerve stimulation (placebo)
Number of subjects: 20
Study: 4620372

Group type: EXPERIMENTAL
Intervention: Butibufen
Number of subjects: 21
Study: 31487271

Group type: EXPERIMENTAL
Intervention: Linked dual-class drug resistance mutations (DRMs) present before ART initiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linked single-class drug resistance mutations (DRMs) present before ART initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination ART with 3 drugs (nevirapine/tenofovir/emtricitabine)
Number of subjects: 0
Study: 28991344

Group type: EXPERIMENTAL
Intervention: Topical and systemic treatment (oral propranolol 1 mg/kg per day initially, increased to 2 mg/kg per day gradually in 2 weeks and timolol maleate 0.5% gel)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Systemic treatment only (oral propranolol 1 mg/kg per day initially, increased to 2 mg/kg per day gradually in 2 weeks and simple eye ointment)
Number of subjects: 25
Study: 27306492

Group type: EXPERIMENTAL
Intervention: 500 mg oral chlorzoxazone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 24935081

Group type: EXPERIMENTAL
Intervention: Standard care plus home-based education
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Home-based education for invitees
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Home-based education
Number of subjects: 163
Study: 22016348

Group type: EXPERIMENTAL
Intervention: Metformin (n = 17)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 30
Study: 19535243

Group type: EXPERIMENTAL
Intervention: CEF (adjuvant epirubicin-based chemotherapy)
Number of subjects: 647

Group type: COMPARATOR
Intervention: CMF (adjuvant methotrexate-based chemotherapy)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: TIMP-1 status (positive or negative) versus treatment (CMF or CEF) interaction
Number of subjects: 647
Study: 17513798

Group type: EXPERIMENTAL
Intervention: Bridging ELISA
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Biacore biosensor immunoassay
Number of subjects: 1216
Study: 15293606

Group type: EXPERIMENTAL
Intervention: One-stage LAUP treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (simulated snore surgery followed by an oral placebo)
Number of subjects: 25
Study: 11887802

Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate-based solution (B/L)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Lactate-based control solution (C)
Number of subjects: 92
Study: 9512112

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg + Amoxicillin 1.5 g (LA group; 21 patients)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg + Amoxicillin 1.5 g + Rebamipide 300 mg (LAM group; 36 patients)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: LAM group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study: 7802317

Group type: EXPERIMENTAL
Intervention: Acelysin (water-soluble acetylsalicylic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acelysin infusion
Number of subjects: 0
Study: 3054452

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) followed 1 hour later by 5‐fluorouracil (5‐FU) (sequence MF)
Number of subjects: 127

Group type: COMPARATOR
Intervention: 5‐fluorouracil followed after 1 hour by methotrexate (sequence FM)
Number of subjects: 127
Study: 29579482

Group type: EXPERIMENTAL
Intervention: Recorded maternal voice
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Breast milk odor
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Incubator cover
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 136
Study: 27370231

Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham meditation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 120
Study: 24737198

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS applied ipsilaterally to the temporoparietal junction (n = 30)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS applied contralaterally to the temporoparietal junction (n = 31)
Number of subjects: 61
Study: 24423909

Group type: EXPERIMENTAL
Intervention: Nutritional liquid supplement designed for diabetes mellitus
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (common diet)
Number of subjects: 69
Study: 19925605

Group type: EXPERIMENTAL
Intervention: Add-on arrhythmia surgery
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cardiac surgery (without add-on surgery)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cardiac surgery (both groups)
Number of subjects: 150
Study: 18715244

Group type: EXPERIMENTAL
Intervention: Intravaginal dinoprostone (2 mg once every 6 hours)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (25 micrograms once every 4 hours)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Transcervical balloon catheter
Number of subjects: 592

Group type: COMPARATOR
Intervention: Intravaginal dinoprostone and intravaginal misoprostol
Number of subjects: 592

Group type: COMPARATOR
Intervention: Intravaginal dinoprostone, intravaginal misoprostol, and transcervical balloon catheter
Number of subjects: 592
Study: 16907931

Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg day‐1; n=13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg day‐1; n=13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combined therapy (quinapril + atorvastatin)
Number of subjects: 26
Study: 12359796

Group type: EXPERIMENTAL
Intervention: Chelation
Number of subjects: 741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 741
Study: 10585386

Group type: EXPERIMENTAL
Intervention: Social Influence (SI) program with boosters
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Social Influence (SI) program without boosters
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Social Influence (Decision-Making) (SI(DM)) program with boosters
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 7851081

Group type: EXPERIMENTAL
Intervention: Calibration for tasks dominated by inference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calibration for tasks dominated by retrieval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response-independence model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response-dependence model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiment 2
Number of subjects: 0
Study: 2088770

Group type: EXPERIMENTAL
Intervention: IdB 1016 (360 mg silybin equivalent)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Silymarin (360 mg silybin equivalent)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IdB 1016 (120 mg b.i.d. for 8 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IdB 1016
Number of subjects: 9
Study: 276348

Group type: EXPERIMENTAL
Intervention: BCG alone
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Tumour cell vaccine
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study: 31976567

Group type: EXPERIMENTAL
Intervention: OSFE with deproteinized bovine bone mineral (Group 1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: OSFE without grafting (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 28541810

Group type: EXPERIMENTAL
Intervention: Carbohydrate-, glutamine-, and antioxidant-enriched oral nutrition supplement (S)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (S and P)
Number of subjects: 18
Study: 27295381

Group type: EXPERIMENTAL
Intervention: Gelfoam patching
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Topical bFGF application
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 0.3% Ofloxacin eardrops (OFLX)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conservative observation
Number of subjects: 185
Study: 24754265

Group type: EXPERIMENTAL
Intervention: Skull vibration-induced nystagmus test (SVINT) with vibratory stimulations at 60 Hz and 100 Hz applied on the vertex and mastoid.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (12 subjects)
Number of subjects: 55
Study: 23537456

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy follow-up (PF) via clinical pharmacy intervention at monthly visits over a 3-month follow-up period
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual treatment (Control Group)
Number of subjects: 68
Study: 20613498

Group type: EXPERIMENTAL
Intervention: Routine stenting with drug-eluting stents (DES) in both branches (group MV plus SB)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Provisional stenting with DES placement in the main branch only (group MV)
Number of subjects: 108
Study: 19010201

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 10 ppm from the start of LT until 48 hours afterward
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no iNO treatment)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 32
Study: 16638037

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard first-line fertility management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin and clomiphene citrate
Number of subjects: 0
Study: 14672246

Group type: EXPERIMENTAL
Intervention: Nutritionally-sourced TRP (1.8 g daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11013378

Group type: EXPERIMENTAL
Intervention: Oral fluconazole (50-200 mg per day)
Number of subjects: 3734
Study: 9283509

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 8345068

Group type: EXPERIMENTAL
Intervention: Follicle-stimulating hormone (FSH) (Metrodin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotrophin (HMG) (Pergonal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pulse interval of 30 min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pulse interval of 120 min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Addition of LH in HMG
Number of subjects: 24
Study: 2942163

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 30248152

Group type: EXPERIMENTAL
Intervention: C-Tb
Number of subjects: 1090

Group type: COMPARATOR
Intervention: TST
Number of subjects: 1090

Group type: COMPARATOR
Intervention: QFT
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: C-Tb and TST
Number of subjects: 1090
Study: 27535024

Group type: EXPERIMENTAL
Intervention: Individually-tailored telephone tobacco intervention combining counseling for tobacco use and related issues including depressive symptoms, risky alcohol use, and weight concerns
Number of subjects: 63

Group type: COMPARATOR
Intervention: Quitline Referral
Number of subjects: 63
Study: 25035121

Group type: EXPERIMENTAL
Intervention: 3mg THC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5mg THC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6.5mg THC
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22586006

Group type: EXPERIMENTAL
Intervention: Comprehensive care management program (CCMP)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 426
Study: 20462632

Group type: EXPERIMENTAL
Intervention: Active art therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 22
Study: 18337480

Group type: EXPERIMENTAL
Intervention: High-dose CVVHDF (35 ml/kg per h)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard-dose CVVHDF (20 ml/kg per h)
Number of subjects: 200
Study: 15968293

Group type: EXPERIMENTAL
Intervention: Anti-CD25 monoclonal antibody (basiliximab)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no basiliximab)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 11211367

Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Combined pharmacotherapy and behavioral treatment
Number of subjects: 198

Group type: COMPARATOR
Intervention: Titration-determined dose
Number of subjects: 198

Group type: COMPARATOR
Intervention: Pharmacological changes
Number of subjects: 198
Study: 9723557

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous pump spray (Rhinocort Aqua) 32, 64, 128, or 256 microg once daily for 6 weeks
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous pump spray (256 microg)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous pump spray (any active treatment group)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous pump spray
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study: 7982869

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg per dose
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.6 mg/kg per dose
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 2567584

Group type: EXPERIMENTAL
Intervention: Atracurium 120 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atracurium 225 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vecuronium 23 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vecuronium 40 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pancuronium 30 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pancuronium 60 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: d-tubocurarine 185 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: d-tubocurarine 450 micrograms/kg
Number of subjects: 10
Study: 5784612

Group type: EXPERIMENTAL
Intervention: Intra-amniotic oestriol sulphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 223601

Group type: EXPERIMENTAL
Intervention: calcium clofibrate and calcium carbonate (4C, 2 + 2 g/day for 6 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: clofibrate (1C, 2 g/day for 6 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: calcium clofibrate and calcium carbonate (4C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: clofibrate (1C)
Number of subjects: 30
Study: 31999518

Group type: EXPERIMENTAL
Intervention: Tell me everything he [or she] eats throughout a day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: What kind of food does she [or he] eat?
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: What kind of foods does he [or she] eat?
Number of subjects: 99

Group type: COMPARATOR
Intervention: Diet history survey
Number of subjects: 99
Study: 30630567

Group type: EXPERIMENTAL
Intervention: Percutaneous Kyphoplasty (PKP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Percutaneous Vertebroplasty (PVP)
Number of subjects: 100